Stock performance of Climb Bio reflects current market trends on Nasdaq.
12 reports, 3 independent
Updated Nov 1
Gone quiet
- Reports
- 12
- Developments
- 3
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Stock performance of Climb Bio reflects current market trends on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Raymond James upgraded Climb Bio rating and Stephen Thomas sold shares.1 source
Director Stephen Thomas sold company stock in Climb Bio.1 source
Climb Bio's stock performance is noted amid general Nasdaq market trends.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- BlackRock analyzes market trends while Nasdaq's poor performance draws investor scrutiny.
- U.S. market performance drives Nasdaq gains.
- BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.
- Arrive AI traded on the Nasdaq stock exchange, with its performance covered by financial blog MarketBeat.